Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | CCNC | P24863 | 2/20 | 0.59 |
| ▸ | CDK8 | P49336 | 2/20 | 0.59 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.50 |
| ▸ | GABRD | O14764 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25324901 | 0.98 | HPGD (0.63) | SIGMAR1HPGDCCNCCDK8SLC6A7 | |
| SCHEMBL20245216 | 0.87 | SIGMAR1 (0.58) | SIGMAR1HPGDCCNCCDK8DRD2 | |
| SCHEMBL8358137 | 0.86 | SIGMAR1 (0.81) | SIGMAR1HPGDMKNK1MKNK2GABRD | |
| SCHEMBL8934917 | 0.85 | SIGMAR1 (0.64) | SIGMAR1HPGDCCNCCDK8MKNK1 | |
| SCHEMBL11193016 | 0.84 | SIGMAR1 (0.55) | SIGMAR1HPGDCCNCCDK8DRD2 | |
| SCHEMBL10264405 | 0.84 | ALDH1A1 (0.62) | HPGDSLC6A7DRD3DRD2ADRB2 | |
| SCHEMBL300831 | 0.84 | HPGD (0.68) | HPGDSLC6A7ADRB2KMT2AMEN1 | |
| SCHEMBL12075414 | 0.83 | HRH4 (0.48) | SIGMAR1HPGDCCNCCDK8SLC6A7 | |
| SCHEMBL21321950 | 0.83 | HPGD (0.71) | HPGDSLC6A7ADRB2KMT2AMEN1 | |
| SCHEMBL7901274 | 0.83 | HPGD (0.71) | HPGDSLC6A7ADRB2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| CN-118515799-A | Process for preparing solid support of procatalyst suitable for olefin polymerization | SABIC环球技术有限责任公司 | 2024-08-20 | — | — | CN | disclosed |
| EP-3519457-B1 | PROCESS TO PREPARE PROCATALYST FOR POLYMERIZATION OF OLEFINS | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2024-06-12 | — | — | EP | disclosed |
| EP-3596140-B1 | PROCESS FOR PREPARING A PROCATALYST FOR POLYMERIZATION OF OLEFINS | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2024-03-20 | — | — | EP | disclosed |
| EP-3310822-B1 | PROCATALYST FOR POLYMERIZATION OF OLEFINS COMPRISING AN AMINOBENZOATE INTERNAL DONOR AND A 1,3-DIETHER INTERNAL DONOR IN A SPECIFIC RATIO | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| US-20220362396-A1 | AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2022-11-17 | — | — | US | disclosed |
| US-11254757-B2 | Process to prepare a solid support for a procatalyst suitable for polymerization of olefins | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2022-02-22 | — | — | US | disclosed |
| US-11254758-B2 | Process for preparing a procatalyst for polymerization of olefins | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2022-02-22 | — | — | US | disclosed |
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2010017122-A2 | METHODS OF TREATING THALASSEMIA | TARGEGEN INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| CN-101022806-A | Use of (4-alkylpiperazinyl)(phenyl) methanones in the treatment of alzheimer's disease | SAMARITAN PHARMACEUTICALS INC (US) | 2007-08-22 | — | — | CN | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | SIGMAR1 1178/4885HPGD 3352/4885CCNC 529/4885 |
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | SIGMAR1 3381/4885HPGD 360/4885CCNC 3778/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | SIGMAR1 1178/4885HPGD 3352/4885CCNC 529/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | SIGMAR1 1178/4885HPGD 3352/4885CCNC 529/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | SIGMAR1 1178/4885HPGD 3352/4885CCNC 529/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | SIGMAR1 35/4885HPGD 352/4885CCNC 654/4885 |
| US-20220362396-A1 | AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF | TGFBR2, SMAD2, ACVR2A | SIGMAR1 3149/4885HPGD 1870/4885CCNC 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.